Athersys

Athersys Operating Expenses

Delisted·Oct 1, 2026

The Total Operating Expenses of Athersys (ATHXQ) as of Nov 20, 2026 is 80.91 M USD. In the previous year, Total Operating Expenses was 91.15 M USD — a change of -11.22% (lower).

Operating Expenses

80.91 MUSD

YoY

-11.22%

Last updated:

Total Operating Expenses of Athersys is 2022 80.91 M USD. Total Operating Expenses of Athersys was 2021 91.15 M USD. It decreases by -11.22% lower compared to the previous year.

The Athersys Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2015
29.12 M USD
Jan 1, 2016
33.05 M USD
Jan 1, 2017
36.99 M USD
Jan 1, 2018
49.96 M USD
Jan 1, 2019
50.42 M USD
Jan 1, 2020
78.88 M USD
Jan 1, 2021
91.15 M USD
Jan 1, 2022
80.91 M USD
The Athersys Operating Expenses history
YEAROperating ExpensesYoY
80.91 MUSD-11.22%
91.15 MUSD+15.55%
78.88 MUSD+56.44%
50.42 MUSD+0.93%
49.96 MUSD+35.06%
36.99 MUSD+11.92%
33.05 MUSD+13.50%
29.12 MUSD-4.96%
30.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Total Operating Expenses of Athersys is 80.91 M USD in 2022.

Total Operating Expenses of Athersys changed from 91.15 M USD to 80.91 M USD, representing a -11.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Athersys since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Athersys

All Key Metrics — Athersys